Literature DB >> 2310513

Could Swedish 'yellow cards' be substituted by E-coded summaries?

C Jorup-Rönström1, M Keisu, B E Wiholm.   

Abstract

Case summaries of 2490 patients treated at the Department of Infectious Diseases, Danderyd Hospital, in 1986 were reviewed for discharge diagnoses where the International Classification of Disease (ICD) code indicated an adverse drug reaction (ADR) [E 939,9 in ICD 8]. Of 48 patients whose case summaries indicated an ADR, only 10 (21%) had been reported on 'yellow cards' to the Swedish Adverse Drug Reactions Advisory Committee. The Committee had also received from the same department 3 reports where the case summary lacked an ADR code. The information on drug treatment with respect to dosage, duration and treatment with concomitant drugs was not complete in the case summaries but sufficient for a preliminary evaluation of the suspected reactions in all but 4 of the cases. On the basis of these findings the authors do not reach an outright conclusion in favour of replacing the 'yellow card' system but the possible benefits of a system in which 'yellow cards' are supplemented by automatic referral of all case summaries containing an ICD code indicating an adverse drug reaction was judged sufficient to recommend and initiate a large field study.

Entities:  

Mesh:

Year:  1990        PMID: 2310513     DOI: 10.2165/00002018-199005010-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  9 in total

1.  Guillain-Barré syndrome following zimeldine treatment.

Authors:  J Fagius; P O Osterman; A Sidén; B E Wiholm
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-01       Impact factor: 10.154

2.  [New rules in reporting adverse effects of drugs].

Authors:  L E Böttiger
Journal:  Lakartidningen       Date:  1974-12-18

Review 3.  Voluntary systems of adverse reaction reporting--Part II.

Authors:  J P Griffin; J C Weber
Journal:  Adverse Drug React Acute Poisoning Rev       Date:  1986

4.  The nosocomial component of medical care. A prospective study on the amount, spectrum and costs of medical disturbances in a department of infectious diseases.

Authors:  C Jorup-Rönström; S Britton
Journal:  Scand J Infect Dis Suppl       Date:  1982

5.  [Who reports on the side effects of drugs?].

Authors:  L E Böttiger; R Hast; L Holmberg
Journal:  Lakartidningen       Date:  1979-03-07

6.  [Registration of drug adverse effects at the University of Upsala Hospital].

Authors:  G Boman; C Claesson; P Göranson
Journal:  Lakartidningen       Date:  1980-05-21

7.  Drug-induced blood dyscrasias in Sweden.

Authors:  L E Böttiger; B Westerholm
Journal:  Br Med J       Date:  1973-08-11

8.  Efficacy of reporting systems of adverse reactions to drugs and care.

Authors:  C Jorup-Rönström; S Britton
Journal:  Scand J Soc Med       Date:  1983

9.  Drug-induced neutropenia--a survey for Stockholm 1973-1978.

Authors:  P Arneborn; J Palmblad
Journal:  Acta Med Scand       Date:  1982
  9 in total
  4 in total

1.  Adverse drug reactions in patients admitted to hospital identified by discharge ICD-10 codes and by spontaneous reports.

Authors:  A R Cox; C Anton; C H Goh; M Easter; N J Langford; R E Ferner
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

Review 2.  Clinical features and management of severe dermatological reactions to drugs.

Authors:  M C Raviglione; A Pablos-Mendez; R Battan
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

3.  Prescribing errors in patients with documented drug allergies: comparison of ICD-10 coding and written patient notes.

Authors:  Arwa Benkhaial; Jens Kaltschmidt; Elke Weisshaar; Thomas L Diepgen; Walter E Haefeli
Journal:  Pharm World Sci       Date:  2009-05-03

4.  The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty.

Authors:  Miran Brvar; Nina Fokter; Matjaz Bunc; Martin Mozina
Journal:  BMC Clin Pharmacol       Date:  2009-05-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.